[
  {
    "title": "Presentation - Evaluate",
    "url": "https://www.evaluate.com/wp-content/uploads/2024/02/World-Preview-Webinar_FINAL_0.pdf",
    "domain": "evaluate.com",
    "lang": "en",
    "type": "PDF",
    "link_only": false,
    "content_type": "application/pdf",
    "size_bytes": 708447,
    "fetch_status": "ok",
    "summary": "PHARMA’S AGE OF\nUNCERTAINTY\nWORLD PREVIEW 2023 TO 2028\n\n\n1 Evaluate 2023   I   Copyright © 2023 Evaluate Ltd. All rights reserved.   Source: Evaluate Pharma© (Jun 2023)\n\fTODAY’S PRESENTERS\nWorld preview 2022 to 2023\n\n\n\n\n                                                                                                                  PAUL VERDIN\n                                                                                                                  VP, Head of Consulting"
  },
  {
    "title": "TRANSFORM - Evaluate",
    "url": "https://www.evaluate.com/wp-content/uploads/2023/11/Evaluate-Omnium-Brochure.pdf",
    "domain": "evaluate.com",
    "lang": "en",
    "type": "PDF",
    "link_only": false,
    "content_type": "application/pdf",
    "size_bytes": 838695,
    "fetch_status": "ok",
    "summary": "TRANSFORM\nasset potential assessment\nwith a richer understanding\nof risk and return.\n\n\n\n\nIn today’s complex biopharma landscape, you need\nan accurate and complete view of the market, so\nyou can thoroughly assess the development risk and\ncommercial potential of assets in development.\n\fCLOSE KEY INSIGHT GAPS\nThe biopharma industry continues to invest far more in clinical failure\nthan success."
  },
  {
    "title": "Review - accessdata.fda.gov",
    "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/210496Orig1s017MultidisciplineR.pdf",
    "domain": "fda.gov",
    "lang": "en",
    "type": "PDF",
    "link_only": false,
    "content_type": "application/pdf",
    "size_bytes": 7349592,
    "fetch_status": "ok",
    "summary": "NDA/BLA Multi-disciplinary Review and Evaluation NDA 210496\n               BRAFTOVI® (encorafenib)\n\n               NDA/BLA Multi-disciplinary Review and Evaluation\n\n               Disclaimer: FDA review was conducted in conjunction with other regulatory authorities under\n               Project Orbis. FDA collaborated with Health Canada (HC)."
  }
]